Cargando…

Copper activates HIF-1α/GPER/VEGF signalling in cancer cells

Copper promotes tumor angiogenesis, nevertheless the mechanisms involved remain to be fully understood. We have recently demonstrated that the G-protein estrogen receptor (GPER) cooperates with hypoxia inducible factor-1α (HIF-1α) toward the regulation of the pro-angiogenic factor VEGF. Here, we sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigiracciolo, Damiano Cosimo, Scarpelli, Andrea, Lappano, Rosamaria, Pisano, Assunta, Santolla, Maria Francesca, De Marco, Paola, Cirillo, Francesca, Cappello, Anna Rita, Dolce, Vincenza, Belfiore, Antonino, Maggiolini, Marcello, De Francesco, Ernestina Marianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741443/
https://www.ncbi.nlm.nih.gov/pubmed/26415222
Descripción
Sumario:Copper promotes tumor angiogenesis, nevertheless the mechanisms involved remain to be fully understood. We have recently demonstrated that the G-protein estrogen receptor (GPER) cooperates with hypoxia inducible factor-1α (HIF-1α) toward the regulation of the pro-angiogenic factor VEGF. Here, we show that copper sulfate (CuSO(4)) induces the expression of HIF-1α as well as GPER and VEGF in breast and hepatic cancer cells through the activation of the EGFR/ERK/c-fos transduction pathway. Worthy, the copper chelating agent TEPA and the ROS scavenger NAC prevented the aforementioned stimulatory effects. We also ascertained that HIF-1α and GPER are required for the transcriptional activation of VEGF induced by CuSO(4). In addition, in human endothelial cells, the conditioned medium from breast cancer cells treated with CuSO(4) promoted cell migration and tube formation through HIF-1α and GPER. The present results provide novel insights into the molecular mechanisms involved by copper in triggering angiogenesis and tumor progression. Our data broaden the therapeutic potential of copper chelating agents against tumor angiogenesis and progression.